Collagen Type I/III vs Type II: Targeted Comparison for Skin, Joints & Beyond
Type I/III collagen supports skin, hair, and tendons; Type II targets cartilage and joint comfort. Pick the right collagen for your specific goal.
The Short Version
Type I/III collagen may better support skin elasticity, hair strength, and tendon integrity, while Type II specifically targets cartilage matrix composition. Choose Type I/III for cosmetic and structural concerns; choose Type II if joint cartilage support is your primary goal. Many people benefit from both.
Recommended Products
Collagen Type I / III (skin, hair, nails, tendons)
Collagen Type II (joint cartilage)
Want the checklist behind these comparisons?
Use the free cheat sheet to compare evidence quality, serving cost, third-party testing, and interaction flags across supplement options.
This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Key Differences
| Factor | Collagen Type I / III (skin, hair, nails, tendons) | Collagen Type II (joint cartilage) |
|---|---|---|
| Primary Structural Location | Type I/III comprise ~90% of skin dermis, ~85% of tendon dry weight, and significant portions of bone matrix and fascia. Type I is most abundant; Type III provides elasticity. | Type II comprises 50–70% of articular cartilage dry weight and is the dominant collagen in hyaline cartilage. Minimal presence in skin or tendons. |
| Bioavailability & Absorption | Hydrolyzed Type I/III (peptide molecular weight 2–5 kDa) shows 90%+ oral absorption in animal models. Human studies suggest peak serum levels 1–2 hours post-ingestion (PMID: 24684551). Amino acid profile enriched in glycine and proline supports collagen synthesis. | Hydrolyzed Type II shows similar absorption kinetics (~85–90%) but collagen-specific dipeptides (hydroxyproline-glycine) may have preferential cartilage targeting via oral tolerance mechanisms (PMID: 28335604). Less direct evidence for serum accumulation compared to Type I/III. |
| Clinical Evidence for Intended Targets | Skin: 8–12 week supplementation associated with improved skin hydration and elasticity in 3 RCTs (mean n=60–69). Hair & nails: limited RCT data; mostly observational or in vitro. Tendons: one 12-week pilot (n=31) showed reduced tendon stiffness on ultrasound elastography (PMID: 31884585). | Joint cartilage & OA: 10+ RCTs over 2–6 months show modest improvements in joint pain scores (mean 10–15% reduction) and cartilage biomarkers (COMP, CTX-II) in mild-to-moderate OA. Meta-analysis suggests NNT ~6–8 for clinically meaningful pain relief (PMID: 28335604). |
| Cost per Daily Dose | Typical retail: $0.15–$0.35/day (10 g dose). Multi-type blends (I/III + II) range $0.25–$0.50/day. | Typical retail: $0.20–$0.40/day (10 g dose). Slightly higher due to additional processing and lower production volume. |
| Synergy & Complementary Nutrients | Often combined with vitamin C (hydroxylation of proline/lysine), copper, and silicon to support synthesis. Ascorbic acid requirement ~200 mg/day for collagen cross-linking. | Often combined with glucosamine, chondroitin, and hyaluronic acid for cartilage matrix support. Vitamin C remains critical. Less evidence for synergy multiplier vs. standalone. |
Best For
Skin elasticity and hydration
Type I/III peptides accumulate in skin and may upregulate dermal fibroblast collagen synthesis. Three RCTs show 4–8% improvements in elasticity and hydration over 8–12 weeks.
Hair and nail strength
Type I/III form the structural matrix of hair follicles and nail beds. While RCT evidence is limited, observational data and cosmetic industry practice suggest supplementation may support keratin synthesis. Type II has no known role in hair or nails.
Tendon and ligament integrity
Type I comprises ~85% of tendon dry mass. One pilot study (n=31) found 12-week Type I/III supplementation reduced tendon stiffness on elastography. Type II is absent from tendons.
Cartilage support and mild osteoarthritis pain
Type II is the dominant structural collagen in articular cartilage. Meta-analyses of 10+ RCTs show 10–15% pain reduction in mild-to-moderate OA over 2–6 months, with biomarker evidence of reduced cartilage turnover. Type I/III has no established role in cartilage.
Bone density and fracture resilience
Type I collagen comprises ~30% of bone organic matrix and provides tensile strength. Type I/III supplementation combined with calcium and vitamin D may support bone remodeling, though dedicated RCTs in humans are limited. Type II is not a component of bone.
Evidence Snapshot
Type I and III collagen products are used mainly for skin outcomes, and the human evidence is modest rather than definitive. Individual randomized trials and meta-analyses report improvements in hydration, elasticity, or wrinkles, but recent higher-level reviews note that effect estimates are sensitive to study quality and funding source. So there is signal for benefit, but the skin literature should be interpreted cautiously rather than as settled proof. Type II collagen is more often positioned for joint support, especially osteoarthritis. Randomized trials of undenatured type II collagen and newer meta-analytic syntheses suggest possible improvements in pain or function in some populations, but effect sizes are not dramatic and the literature mixes different collagen derivatives, doses, and clinical contexts. In practice, Type I/III is the better fit for skin-focused goals, while Type II is the more relevant form for joint-focused goals. ### Angelique review update: collagen targeting limits Collagen accounts for roughly 30% of the body's protein, but swallowed collagen peptides cannot be directed to a specific tissue on demand. Hydrolyzed collagen is digested into peptides and amino acids; those building blocks may support skin, tendon, or cartilage biology, but the body decides where they are used. That is why Type I/III versus Type II positioning should be framed as targeted evidence and ingredient rationale, not a guarantee that peptides travel directly to skin or joints. Research-bias caveat: many collagen trials are industry-funded or involve investigators with commercial ties. That does not invalidate the data, but it means effect sizes should be read with funding context in mind. Food-first note: adequate dietary protein, vitamin C, zinc, copper, sleep, sun protection, and avoiding smoking/excess sugar all influence collagen biology. Supplements are an add-on, not a substitute for those inputs.
Safety & Interactions
- Pregnancy and breastfeeding: Consult your healthcare provider before taking this supplement during pregnancy or while nursing. The safety of supplemental doses beyond dietary intake has not been established in pregnant or lactating women.
- Blood thinners: If you take blood-thinning medications (e.g., warfarin, apixaban, rivaroxaban, clopidogrel, or high-dose aspirin), consult your healthcare provider BEFORE starting this supplement, as it may have additive antiplatelet or anticoagulant effects.
- Kidney disease: If you have chronic kidney disease (CKD) or any significant kidney impairment, consult your healthcare provider before taking this supplement. Some supplements can accumulate to dangerous levels when kidney function is reduced.
- Gout: Individuals with gout should consult their healthcare provider before starting this supplement. Certain supplements (e.g., collagen, fish oil, niacin) may affect uric acid levels or trigger flares in susceptible individuals.
- Fish / shellfish allergy: If you have a confirmed fish or shellfish allergy, check the source of this supplement carefully. Some products (e.g., marine collagen, fish oil, glucosamine from shellfish) are derived from fish or shellfish and may trigger allergic reactions.
- Beef allergy: If you have a confirmed beef allergy or alpha-gal syndrome (mammalian meat allergy), avoid supplements derived from bovine sources, including collagen, gelatin, and some forms of cartilage. Look for marine or vegan alternatives.
- Autoimmune disease (UC-II collagen): If you have an autoimmune condition involving collagen (e.g., rheumatoid arthritis, lupus, scleroderma, or relapsing polychondritis), consult your rheumatologist before taking UC-II (undenatured type II collagen). The theoretical concern is that oral collagen could modulate immune tolerance, though clinical evidence of harm is lacking. Some studies actually show benefit in rheumatoid arthritis, but individual responses vary.
- Important: This supplement is not a replacement for prescription medications. It is supportive for individuals with low baseline status, not a treatment for diagnosed conditions (anxiety disorders, insomnia, hypertension, osteoporosis, etc.). Do not stop or reduce any prescription without consulting your doctor.
This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Always consult your healthcare provider before starting any supplement.
Frequently Asked Questions
If skin elasticity is your primary goal, our guide on collagen for skin health compares hydrolysate dose ranges, bioavailability data, and which clinical trial designs actually isolate skin outcomes.
For cartilage and mobility goals, our page on collagen for joint health reviews UC-II undenatured Type II evidence vs hydrolysate, and how it stacks with glucosamine or hyaluronic acid.
Interested in hair and nail applications? Our collagen for hair growth page covers the dermal matrix evidence, amino acid cofactor roles, and how Type I collagen supports follicle structural integrity.